Our immune system is armed with an array of defenses designed to detect and eliminate harmful threats. One of its most powerful defense mechanisms is the complement system—a group of proteins that ...

Antibody drugs have reshaped how we treat diseases. By harnessing the immune system to destroy tumours or temper excessive inflammation in autoimmune disorders, these therapeutics have become ...

Use of a sodium-glucose cotransporter 2, or SGLT2, inhibitor combined with calorie restriction resulted in greater rates of type 2 diabetes remission compared with calorie restriction alone, according ...

MHH research team disables tumour cells with synthetic Adhibin and prevents migration and attachment to other cells ...

Ministry of Health, Labour and Welfare to evaluate ACP as potential first and only treatment for patients with geographic atrophy (GA) secondary to ...

Research has shown that a potential new targeted therapy for childhood brain cancer is effective in infiltrating and killing tumor cells in preclinical models tested in mice. The novel drug CT-179 was ...

Request To Download Free Sample of This Strategic Report @ Highlighted with 43 tables and 86 figures, this 160-page report ?Europe Biopharmaceuticals Market 2023-2033 by Product Type, Testing Service ...

Request To Download Free Sample of This Strategic Report @ Highlighted with 78 tables and 119 figures, this 215-page report ?Global Biopharmaceuticals Market 2023-2033 by Product Type, Testing ...

An MTF2-containing subcomplex of Polycomb Repressive Complex 2 promotes cell cycle progression through repression of D-type cyclin expression in certain cellular contexts.

As we observe World Cancer Day today, let us look at some of the trends in cancer therapeutics expected to improve cancer ...

Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...

Cantor Fitzgerald analysts initiated coverage of Acrivon Therapeutics Inc (NASDAQ:ACRV) with an Overweight rating. The initiation comes with a positive outlook on the company's potential in the field ...